Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 24, 2017
Pharmacy Choice - Pharmaceutical News - Rheumatoid Arthritis Therapeutics in South-East Asia Market Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs - September 24, 2017

Pharmacy News Article

 9/12/17 - Rheumatoid Arthritis Therapeutics in South-East Asia Market Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis Therapeutics: Global Industry Analysis, Capacity, Production, Price, Revenue, Size, Share, Growth, Trends, and Forecasts 2017-2024Lawndale, CA (SBWIRE) 09/12/2017 Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFsSummary
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.Request Sample Report @https://goo.gl/f5bVoRThe chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-? inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-? inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-? inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition. As a result, these biological therapies are not recommended to patients who are susceptible to infection.Obtain report details @http://www.provueresearch.com/product/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022-novel-jak-and-il-6-receptor-inhibitors-to-stimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs/In addition, there is a need to create biologics with more convenient and less invasive drug-delivery methods, as all existing therapies are administered subcutaneously or intravenously. These routes of administration are frequently associated with pain, rash, and allergic reactions at the injection or infusion site, and in the case of infusion flu-like illness, fever, chills, nausea, and headache. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.Although the recently approved drug Xeljanz is an orally administered small-molecule drug, indicated as a second-line treatment for RA patients who have not shown an adequate response to methotrexate, and as a third-line therapy for patients who have not responded sufficiently to biologics, it carries a black-box warning in the US due to the safety issues of serious infections and malignancy.ScopeThe current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.
What are the competitive advantages of the existing novel drugs?
There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
Which classes of novel drugs are most prominent in the pipeline?
What is the potential for pipeline products to address unmet needs in the RA market?
Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
How do failure rates vary by stage of development, molecule type, and molecular target?
How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
Which markets make the most significant contribution to the current market size?
What are the epidemiology trends in these markets?
Will new market entrants lead to substantial changes in annual therapy costs?
How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?Do you have any Inquiry Before purcashing please fill the form @https://goo.gl/CSzi8SReasons to buyThis report will enable you to
Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.About Provue Market Research
Provue Market Research is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles.For more information on this press release visit: http://www.sbwire.com/press-releases/rheumatoid-arthritis-therapeut/release-862796.htm

Media Relations Contact

Elizabeth Salzar
Telephone: 1-888-920-4862
Email: Click to Email Elizabeth Salzar
Web: http://www.provueresearch.com/product/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022-novel-jak-and-il-6-receptor-inhibitors-to-stimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs/




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 24: Using Effective Communication to Reduce Medication Errors
Last Chance
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415